Bioatla, Inc. (BCAB)
NASDAQ:BCAB
Want to see BCAB full AI Analyst Report?
BCAB Stock Chart & Stats
$0.19
-$0.03(-5.55%)
At close: 4:00 PM EST
$0.19
-$0.03(-5.55%)
Day’s Range― - ―
52-Week Range$3.26 - $71.50
Previous CloseN/A
Volume775.41K
Average Volume (3M)35.42K
Market Cap
$6.12M
Enterprise Value$8.79M
Total Cash (Recent Filing)$1.96M
Total Debt (Recent Filing)$6.09M
Price to Earnings (P/E)―
Beta1.96
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-41.72
Shares Outstanding1,659,612
10 Day Avg. Volume30,009
30 Day Avg. Volume35,421
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.92
Price to Sales (P/S)16.70
P/FCF Ratio-0.69
Enterprise Value/Market Cap1.43
Enterprise Value/Revenue4.39
Enterprise Value/Gross Profit4.15
Enterprise Value/Ebitda-0.18
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-46
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary CAB PlatformBioAtla’s Conditionally Active Biologic (CAB) platform is a structural competitive asset: antibodies preferentially activated in tumor microenvironments can materially reduce systemic toxicity. That technological differentiation creates a durable moat that supports long-term partner interest, licensing, and premium positioning for oncology therapeutics.
Clinical-stage Oncology PipelineMaintaining a clinical-stage pipeline provides multiple lasting value inflection points via data readouts, potential licensing, or asset sales. Even with constrained cash, clinical assets create optionality that can be monetized or partnered, preserving upside across a 2–6 month horizon and beyond as trial milestones or partner interest materialize.
Capital-structure Consolidation ActionThe executed 1-for-50 reverse split and internal merger are structural steps to tighten capital structure and preserve the company’s charter. Such corporate actions can help address listing requirements, reduce administrative friction, and improve the company’s readiness for financing or strategic transactions over the coming months.
Bears Say
Heavy Cash BurnPersistent, large cash outflows create a structural financing need. With TTM OCF at -$37.3M and FCF -$23.1M the company must rely on external financing or asset monetization to sustain operations. That chronic burn elevates dilution risk and makes multi-period execution of trials contingent on successful capital-raising or partnerships.
Weakened Balance SheetNegative equity and a sharply reduced asset base materially constrain financial flexibility. A deteriorated balance sheet limits borrowing capacity, raises creditor and listing scrutiny, and increases the likelihood that management must pursue dilutive financings or asset sales rather than fund development organically.
Major Restructuring And Program DelaysA ~70% headcount reduction and program reprioritization are structural hits to execution capacity. Reduced internal R&D and delayed trials diminish the company’s ability to advance or de-risk clinical programs, lowering the probability of near-term value-creating milestones and making outcomes more dependent on external collaborators.
BioAtla News
BCAB FAQ
What was Bioatla, Inc.’s price range in the past 12 months?
Bioatla, Inc. lowest stock price was $3.26 and its highest was $71.50 in the past 12 months.
What is Bioatla, Inc.’s market cap?
Bioatla, Inc.’s market cap is $6.12M.
When is Bioatla, Inc.’s upcoming earnings report date?
Bioatla, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 73 days.
How were Bioatla, Inc.’s earnings last quarter?
Currently, no data Available
Is Bioatla, Inc. overvalued?
According to Wall Street analysts Bioatla, Inc.’s price is currently Overvalued.
Does Bioatla, Inc. pay dividends?
Bioatla, Inc. does not currently pay dividends.
What is Bioatla, Inc.’s EPS estimate?
Bioatla, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bioatla, Inc. have?
Bioatla, Inc. has 1,659,612 shares outstanding.
What happened to Bioatla, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Bioatla, Inc.?
Currently, no hedge funds are holding shares in BCAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bioatla, Inc.
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
Technical Analysis
Actinium Pharmaceuticals
―
―
Lantern Pharma
―
Century Therapeutics
―
MAIA Biotechnology, Inc.
―
Ownership Overview
Currently, No data available
---